Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedtideHKSE:03880 +1.82%23 FCF Margin % is -7.03% as of Dec. 2025. GuruFocus rates HKSE:03880 with a GF Score™ of 23/100. Among 960 Biotechnology companies, Medtide ranks better than 91.98% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Medtide's Free Cash Flow for the
six
months ended in Dec. 2025 was HK$-24.6 Mil. Medtide's Revenue for the
six
months ended in Dec. 2025 was HK$349.4 Mil. Therefore, Medtide's FCF Margin % for the quarter that ended in Dec. 2025 was -7.03%.
The historical data trend for Medtide's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:03880 vs VRTX, REGN, MRNA: FCF Margin % Comparison
For the Biotechnology subindustry, Medtide's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medtide FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medtide's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Medtide's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medtide (HKSE:03880) has a FCF Margin % of -7.03% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medtide and its competitors. Over the past decade, Medtide's FCF Margin % has ranged from 9.70 to 30.71. According to the industry distribution chart, Medtide ranks #77 out of 960 companies in the Biotechnology industry, placing it in the top 8%.
Is Medtide's FCF Margin % too high?
Medtide's current FCF Margin % is -7.03%. Over the past 10 years, this metric has ranged from a low of 9.70 to a high of 30.71. Based on the distribution chart, Medtide ranks #77 out of 960 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Medtide has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Medtide's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medtide ranks #77 out of 960 companies for FCF Margin %. This places Medtide in the top 8% of its industry — outperforming the majority of peers. Historically, Medtide's own FCF Margin % has ranged from 9.70 to 30.71 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Medtide and its competitors. Medtide's current FCF Margin % is -7.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medtide stock overvalued right now?
Medtide (HKSE:03880) has a current FCF Margin % of -7.03%. The current FCF Margin % is -7.03%. Medtide's overall GF Score™ is 23/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Medtide (HKSE:03880), the current FCF Margin % is -7.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Medtide Inc offers full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. It mainly provide (i) CRO services, namely peptide NCE discovery synthesis; and (ii) CDMO services, namely peptide CMC development and commercial manufacturing. Its services focus on providing customers with APIs rather than drug products. Geographically, the company generates majority of its revenue from USA.
23GF Score
Get the complete analysis for HKSE:03880
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:03880 has been successfully added to your 
